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Background: The alarming prevalence of heart failure with preserved ejection fraction requires quantiﬁcation of
diastolic dysfunction (DDF). Myocardial diastolic velocity E′ implies that age is the most important determinant.
We tested the hypothesis that age allows for quantiﬁcation of DDF and assessment of the structural andmetabol-
ic determinants in patients with and without type 2 diabetes (D).
Methods: This prospective, cross-sectional study assessed cardiovascular, metabolic and ultrasound data in 409
consecutive patients (Diabetes Center, Bogenhausen-Munich) between 20 and 90 years without known cardiac
disease and either with (n = 204) or without D but with common prevalence of cardiovascular risk factors, in-
cluding a subgroup of healthy individuals (H, n = 94).
Results: In H, E′ related to age as: E′norm =−0.163 ∗ years + 19.69 (R2 = 0.77, p b 0.0001). According to this 1%
reduction by annual physiologic aging, DDFwas quantitated as E′− E′ norm. Compared to nondiabetics, D patients
were older, had greater BMI, lower E′, more cardiovascular risk and greater DDF. In nondiabetics, grading of DDF
by E− E′norm correlated with grading by ﬁlling pressure E/E′. Determinants of DDF by multivariate analysis in-
cluded pulse wave velocity, diastolic blood pressure and the triglyceride/HDL ratio (a marker of insulin resis-
tance) in nondiabetics and in D the same risk factors in reverse sequence and heart rate. Neither left atrial size
nor left ventricular mass had signiﬁcant impact.
Conclusions: The physiological impact of age on myocardial function consists of a 1% annual reduction in E′ and
enables precise quantiﬁcation of diastolic dysfunction thereby unmasking the importance of metabolic risk for
DDF.
© 2014 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction
Approximately half of the patients with heart failure have predomi-
nantly diastolic dysfunction and preserved left ventricular ejection frac-
tion (HFpEF). Although prognosis is as ominous as that of systolic heartiabetes and Vascular Medicine,
lity for all aspects of the reliabil-
heir discussed interpretation.
dded important content to the
ing.
land Ltd. This is an open access article ufailure, there is still no effective treatment for HFpEF [1]. This is due to a
number of factors that include an incomplete understanding of diastolic
dysfunction and the pathophysiological mechanisms of HFpEF [2–4].
Another potential cause is the lack of consensus regarding validation
and diagnosis of diastolic dysfunction [4–6] that complicates entry
criteria for clinical trials. Diastolic dysfunction and the development of
HFpEF increase with age but there is a lack of age-adjusted reference
standards for diastolic dysfunction measurements [4]. Based on a
pilot study inwhichwe quantiﬁed normal diastolic myocardial function
E′norm from the close correlation between tissue Doppler derived E′ and
age [7], we tested the hypothesis that the comparison of measured E′ to
the calculated E′norm allows quantiﬁcation of diastolic dysfunction as the
respective difference. Furthermore, this method provides a better un-
derstanding of diastolic dysfunction because it assesses cardiac, vascu-
lar, hemodynamic and metabolic determinants independent of normal
aging in patients with and without diabetes.nder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
Table 1
Characteristics of the study population.
Characteristic Non-diabetic control Type 2 diabetes p
Healthy With CV risk
n 94 111 204
Age (years) 48 ± 16 55 ± 14*** 60 ± 11***## b0.001
Men (%) 48 35** 66**### b0.001
BMI (kg/m2) 23 ± 3 31 ± 9*** 31 ± 5*** b0.001
Blood pressure systolic (mm Hg) 119 ± 14 135 ± 17*** 142 ± 21*** b0.001
Blood pressure diastolic (mm Hg) 75 ± 9 82 ± 11*** 83 ± 12*** b0.001
Heart rate (bpm) 67 ± 11 68 ± 11 69 ± 11 0.227
LVED (mm) 44 ± 5 45 ± 5 43 ± 5## 0.003
LAVI (ml/m2) 43 ± 18 47 ± 19 54 ± 22***## b0.001
LVMI (g/m2) 74 ± 18 85 ± 29*** 85 ± 20*** b0.001
S′ (cm/s) 8.7 ± 1.3 8.3 ± 1.4* 7.7 ± 1.1***### b0.001
E′ (cm/s) 11.8 ± 2.9 10.0 ± 2.2*** 8.1 ± 1.7***### b0.001
E′ − Enorm (cm/s) 0.0 ± 1.5 −0.7 ± 1.4** −2.0 ± 1.6***### b0.001
E/E′ 6.3 ± 1.6 7.2 ± 1.8* 8.5 ± 2.5***### b0.001
Intima-media thickness (mm) 0.56 ± 0.14 0.67 ± 0.15*** 0.69 ± 0.16*** b0.001
HbA1c (%) 5.6 ± 0.3 5.6 ± 0.3 7.4 ± 1.8***### b0.001
Insulin (μIU/ml)§ 4.7 ± 2.7 15.3 ± 17.8** 14.2 ± 11.9* 0.012
HOMA-IR§ 1.0 ± 0.6 3.2 ± 3.7** 4.2 ± 3.3*** 0.002
Triglycerides (mg/dl) 100 ± 40 119 ± 53* 160 ± 97***## b0.001
HDL (mg/dl) 60 ± 16 55 ± 16 49 ± 13***### b0.001
Triglycerides/HDL 1.8 ± 1.0 2.6 ± 1.8** 3.7 ± 2.7***## b0.001
hsCRP (mg/dl) 1.8 ± 4.8 3.5 ± 6.6 4.2 ± 9.9 0.478
Beta blocker (%) 4 26*** 25*** b0.001
ACE inhibitor (%) 0 20*** 39*** b0.001
AT2 receptor blocker (%) 0 15*** 16*** 0.020
Ca channel blocker (%) 0 8 15*** 0.001
Statins (%) 0 22*** 34***## b0.001
*p b 0.05, **p b 0.01 and ***p b 0.001 vs. healthy controls; #p b 0.05, ##p b 0.01 and ###p b 0.001 vs controls with CV risk, § = in subgroup without insulin therapy.
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2.1. Study design
This prospective observational study was designed for 1) quantiﬁcation of diastolic dys-
function via the age dependence of E', 2) comparison of this quantiﬁcation with traditional
parameters of diastolic dysfunction and 3) evaluation of determining factors that are inde-
pendent of normal aging. In order to apply themost robust, sensitive, and generally available
ultrasound technique [8,9] tissue Doppler was performed in consecutive patients referred to
the echocardiographic lab (Clinic for Endocrinology, Diabetes and Vascular Medicine at the
Klinikum Bogenhausen in Munich). From these, 409 individuals with or without metabolic
abnormalities prone to deﬁciency of myocardial energy availability, namely type 2 diabetes,
were selected with the following inclusion (men or women between 20 and 90 years) and
exclusion criteria (LVED N56mm, LVwall thickness N14mm, LVEF b50%, severe arterial hy-
pertension, renal failure [creatinine N 2mg/dl], anemia, untreated thyroid disease, type 1 di-
abetesmellitus and severe systemic disease). Patients were assigned to type 2 diabetes (n=
204) if on anti-diabetic medication and/or by self report. The remainder were non-diabetic
controls (n = 205) representing the average population without diabetes or cardiac disease
(Table 1). A healthy subgroup (H, n= 94) contained individuals without cardiovascular risk
factors and obesity as deﬁned according to theNational Institutes of Health ConsensusDevel-
opment Panel Criteria as body mass index (BMI) N27.2 kg/m2 in men and N27.7 kg/m2 in
women. Arterial hypertension was deﬁned as antihypertensive treatment or systolic blood
pressureN140mmHgand/ordiastolic bloodpressureN90mmHgandhypercholesterolemia
as a low-density lipoprotein cholesterol level N130mg/dl and/or current intake of lipid low-
ering therapy.
The ethical committee relevant for our institution approved the study reﬂecting con-
formity of the study protocol to the ethical guidelines of the 1975 Declaration of Helsinki.
Patients gave informed consent.2.2. Echocardiography
Echocardiograms (ALOKA SSD-5500, Tokyo, Japan) were obtained in all patients by
one experienced sonographer blinded to the patients' clinical data. LV and LA dimensions
were measured and LA volume index and LV mass index were derived as recommended
by the American and European Quantiﬁcation Guidelines [10]. LAVI and LVMI were cate-
gorized into normal size, mildly-moderately abnormal size or severely abnormal size
[10]. Early (E) and late diastolic (A) transmitral velocities were measured by pulsed
wave Doppler. For feasibility assessment of recording LAVI, LVMI, mitral E/A and tissue
Doppler (separately for each apical view), the image quality of the respective recordings
was graded (1 = excellent, 2 = good, 3 = adequate, 4 = difﬁcult, 5 = obscure, 6 = im-
possible) and score ≤4 was considered acceptable quality (Table 3).2.3. Global LV function by tissue Doppler
In the 4-, 2-, and 3-chamber view, pulsed tissue Doppler was recorded at the intersec-
tion of the atrioventricular plane with each LV wall by selecting a) the lowest possible in-
tercostal space for apical imaging, and b) a central position of the LV apex in the imaging
sector. The respective 6 regionalmyocardial velocities were recorded during three consec-
utive cycles and averaged for the assessment of peak systolic (S′), early diastolic (E′) and
late diastolic velocity (A′) as ameasure of global LV function [8,11]. LV ﬁlling pressure was
calculated as E/E′.
Based on thedominant impact of age as independent and unchangeablepredictor var-
iable for E′, the inﬂuence of all other determinants needs mathematical unmasking from
this relation, so that their respective effects may be understood and potentially used for
preventive strategies [4]. Accordingly, the respective regression equation of thehealthy in-
dividuals was applied to calculate the age related normal value (E′norm=−0.163 ∗ age+
19.67) and the respective lower 95% tolerance interval (E′norm — 2.86) for comparison
with E′ in each individual. If the deﬁcit to E′norm (E′− E′norm)was N2.86 cm/s, this individ-
ual was assigned to diastolic dysfunction, and if N50% of this cut off level to risk for dys-
function. The determinants of E′ − E′norm were assessed regarding structural,
hemodynamic and metabolic factors.2.4. Vascular ultrasound
Intima-media thickness and vascular stiffnesswere evaluated in the right common ca-
rotid using a combinedDoppler and echo tracking systemand a 13MHz linear array trans-
ducer as previously described [12]. This radio frequency based echo tracking method
continuously detected changes in carotid diameter. Peak and minimal values were cali-
brated to systolic and diastolic brachial blood pressures so that intravascular pressure
changes, strain pressure elasticity modulus ε and pulse wave velocity (PWV) could be cal-
culated online. Concomitantly, blood pressure was measured three times in the right arm
by an automated cuff sphygmomanometer and averaged.2.5. Biochemistry
Fasting serum glucose, serum insulin, lipid proﬁle and glycated hemoglobin A1c
(HbA1c) were determined according to routine methods at the Department of Clinical
Chemistry of the Städt. Klinikum Bogenhausen, Munich. The triglyceride/HDL ratio was
used as ameasure of insulin resistance for all individuals because of the large number of di-
abetic individuals on insulin therapy in whom the HOMA-IR cannot be applied [13]. In dia-
betic patients, intact proinsulin was measured by ELISA at the IKFE institute, Mainz [14].
Fig. 2. The same regression lines of normal values and 95% tolerance limits. The lower one
(violet) is the cut off value for diastolic dysfunction and the broken line half way between
the latter and the regression line for risk of dysfunction. Patientswith type 2 diabetes (n=
204) demonstrate an even distribution of normal diastolic function, risk for dysfunction
and dysfunction.
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Sample size calculation:Multiple linear regression analysiswas the primary inference
approach for the assessment of the association of diastolic dysfunction and respective ex-
planatory factors. In order to achieve accurate effect estimation and sufﬁcient power
(≥80%) in testing for associations, a sample size of 200 individuals per group was consid-
ered to be appropriate [15] taking into account the need for confounder control: with the
given sample size, simultaneous inclusion of up toﬁve covariateswas feasiblewithout loss
in estimation efﬁciency.
Statistical analysiswas performed using the SPSS version 17.0 software package (SPSS
Inc., Chicago, IL). Data are expressed asmean±standarddeviationwhennormally distrib-
uted and otherwise as median (interquartile range). Students' t-test or nonparametric
tests were used for group comparisons where appropriate. Differences between three
groups were tested by analysis of variance (ANOVA) and Fisher's least signiﬁcant differ-
ence (LSD) test as respective post hoc tests. Due to the lack of age-adjusted reference stan-
dards for diastolic dysfunction measurements [4], 95% tolerance limits were calculated
based on a healthy control group. Accordingly, a linear regression model was employed
regressing E′ on age. Assuming homoscedastic error terms, the lower 95% tolerance limit
was then achieved by subtracting 1.64 times the square root of the residual variance
from the respective age-speciﬁc predicted value of E′ (E′norm). Subsequently, linear regres-
sion analysis was performed to explore potential predictive factors for the magnitude of
dysfunction indiabetic andnon-diabetic patients as deﬁned byE′− E′norm. Only those var-
iables that revealed relevant bivariate correlation with the deﬁned outcome variable
(Pearson correlation coefﬁcient N+0.2 or b−0.2) were entered into multivariate regres-
sion models and respective multivariable (covariate-adjusted) p values and standardized
regression coefﬁcients beta were calculated. All statistical tests were conducted two-sided
at a local level of signiﬁcance of 0.05. No correction of p-values was applied to adjust for
multiple testing. However, results of all statistical tests being conducted were thoroughly
reported so that an informal adjustment of p values can be performedwhile reviewing the
data [16].
Measurements and analysis of ultrasound and of metabolic variables were performed
by staff blinded for relevant patient characteristics and study protocol while the examined
patients and controls were not aware about the predictive role of diastolic dysfunction. In
order to reduce outlier effects and to avoid selection bias in reporting ﬂuctuating individ-
ual data, three single measurements of blood pressure and of tissue Doppler velocities
were collected independently and averaged for each individual. Potential bias in effect es-
timationwas addressed by employingmultivariable regressionmodels for the adjustment
of established confounding factors such as BMI, systolic blood pressure and LV ﬁlling
pressure.3. Results
3.1. Control and diabetes groups
The characteristics of the healthy subgroup, the non-diabetic indi-
viduals with cardiovascular risk and the diabetes group (Table 1) dem-
onstrated the expected signiﬁcant differences in BMI, cardiac data,Fig. 1. E′ over age in 205 nondiabetic controls subdivided by the presence of 3 (full red
dots), 2 (violet circles), 1 (green circles) or no cardiovascular risk factors (full black
dots). The regression line is calculated from the latter, and denotes Enorm surrounded by
the lines of the upper and lower 95% tolerance intervals (in ±2.86 cm/s distance).blood pressure, metabolic variables, cardiovascular risk factors and re-
spective therapies. Duration of diabetes was 9 ± 8 years and 74% of
the diabetic patients were on insulin therapy.
Male and female non-diabetic controls had similar anthropomorphic
and clinical data associated with thewell known gender speciﬁc excep-
tions. Furthermore, they had similar cardiac data and vascular function
(data not shown). The inverse linear regression equation for the relation
of E′ over age formen (y=−0.167 ∗ years+ 19.97)was comparable to
that of women (y=−0.161 ∗ years+19.48) in the healthy subgroupH
and in the total 204 controls (y = −0.16 ∗ years + 19.2 and y =
−0.15 ∗ years + 18.6, respectively) both p b 0.001. Accordingly, male
and female data were pooled in subsequent analysis.
In the healthy subgroup, E′ and age showed a strong and inverse cor-
relation; estimated regression equation: E′norm = −0.163 ∗ years +
19.69, R2 = 0.77, p b 0.0001. In all non-diabetic controls (Fig. 1), the
dominant inﬂuence of age on E′ is demonstrated by the standardized
coefﬁcient beta, that was−0.880 in univariate analysis and remained
dominant inmultivariable analysis with the incremental addition of hy-
pertension (−0.822 and−0.072), dyslipidemia (−0.787,−0.057 and
−0.133) and obesity (−0.804,−0.036,−0.123 and−0.068), respec-
tively. Systolic function S′ and age also had an inverse correlation (esti-
mated S′ = −0.033 ∗ years + 10.30, R2 = 0.153, p b 0.0001) with a
standardized coefﬁcient beta of−0.39.
In the 204 controls, normal function, as deﬁned by E′− E′norm in the
methods section, was assigned to 151 (73%) individuals, risk for dys-
function to 42 (21%) and dysfunction to 12 (6%) (Fig. 1),whereas the re-
spective prevalence in diabetes was 70 (34%), 75 (37%) and 57 (28%)
(Fig. 2).
Severity grading of diastolic dysfunction by E′− E′norm was com-
pared with that based on the traditional parameters E/E′, LAVI and
LVMI (Table 2). In non-diabetic controls, grading by E′ − E′norm had
good agreement to that by the E/E′ ratio, but LAVI overestimated and
LVMI underestimated abnormality. In the diabetes groupwith the even-
ly distributed three dysfunction classes, normal function agreed with
the E/E′ derived grading but themajority of severely abnormal function
was underestimated. Also in diabetes, LAVI overestimated, but LVMI
underestimated abnormality.
The feasibility of measuring diastolic function criteria in all patients
was best with E/A ratio (96%) and tissue Doppler in the 4-chamber
view (95%), followed by that in the 2-chamber view and LVMI by the
Devereux formula (each 91%) and tissue Doppler in the 3-chamber
Table 2
Distribution of dysfunction severity according to functional and structural criteria commonly associated with the assessment of diastolic function.
Control (%) Diabetes (%)
Normal Mildly-moderately abnormal Severely abnormal Normal Mildly-moderately abnormal Severely abnormal
E′ − E′norm 73 21 6 34 37 28
E/E′ 77 23 0 34 63 3
LAVI 30 32 38 17 26 57
LVMI 91 8 1 92 7 1
Severity classes were deﬁned for E/E′ according to the European recommendations on how to diagnose diastolic heart failure [5] and for LAVI and LVMI according to the European and
American recommendations of chamber quantiﬁcation [9].
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overweight population.
3.2. Univariate linear regression analysis
Bivariate correlations were assessed for the associations of E′ −
E′norm in all controls and in diabetes patients (Table 3). Expectedly in
the former, neither age nor sex was signiﬁcantly associated with E′−
E′norm. LAVI and E/E′missed signiﬁcance, but dyslipidemia, pulse wave
velocity, diastolic blood pressure, BMI, serum insulin, lipid levels and
the triglyceride/HDL ratio had signiﬁcant associations. These were also
observed in the diabetes group additionally to heart rate and creatinine
but not for dyslipidemia.
3.3. Multivariable linear regression analysis
For multivariable analysis in all controls, E′− E′ norm was entered as
the dependent variable into the model and signiﬁcant factors from uni-
variate analysis as components of vascular function or cardiac structure
stepwise as the independent variables (Table 4, Models 1 to 4a–g). The
ﬁnal model 5 (R2 0.187, p b 0.001) had PWV, diastolic blood pressure
and triglyceride/HDL ratio as determinants with the standardized coef-
ﬁcients beta−0.336,−0.037 and 0.203, respectively. In type 2 diabetes,
the models with the same determinants in reversed sequence (model 1
to 4a–h) improved further with the addition of heart rate, a surrogate
parameter of cardiac autonomic neuropathy (Model 5, R2 0.195, p b
0.001): insulin resistance, diastolic blood pressure, PWV, and heart
rate had the standardized coefﬁcients beta−0.309,−0.216,−0.143
and−0.187, respectively.Table 3
Correlations for E′ − E′norm.
Non-diabetic
controls
Type 2 diabetes
r p r p
Dyslipidemia −0.380 0.008 −0.007 0.92
E mitral (cm/s) 0.375 b0.001 0.200 0.005
E/A 0.290 b0.001 0.096 0.183
E/E′ −0.155 0.080 −0.141 0.049
LAVI (ml/m2) −0.141 0.061 −0.047 0.53
LVMI (g/m2) −0.122 0.104 −0.102 0.157
Heart rate (bpm) −0.055 0.45 −0.206 0.003
Systolic BP (mm Hg) −0.131 0.077 −0.024 0.73
Diastolic BP (mm Hg) −0.230 0.002 −0.307 b0.001
EPP (kPa) −0.177 0.080 0.055 0.45
PWV (m/s) −0.294 0.004 0.109 0.140
BMI (kg/m2) −0.187 0.011 −0.196 0.006
Glucose (mg/dl) −0.004 0.96 −0.049 0.52
Insulin (µIU/ml) −0.288 0.023
*Intact proinsulin (pmol/l) −0.295* 0.027
Triglycerides (mg/dl) −0.225 0.023 −0.184 0.014
HDL (mg/dl) −0.187 0.020 0.318 b0.001
Tri/HDL −0.204 0.011 −0.285 b0.001
Creatinine (mg/dl) −0.047 0.57 −0.177 0.016
bold letters = level of signiﬁcance p b 0.053.4. Sites of E′ assessment
For evaluating the potential inﬂuence from the selection ofmeasure-
ment sites on the relation of E′ to age, the respective regression equa-
tions were assessed in these 76 healthy individuals who had a
complete data set of tissue Doppler velocity measurements in all 6 seg-
ments from the three apical views. Accordingly, the resulting regression
equation of E′norm is shown as averaged from either 6 measurement
sites, 4 sites (4- and 2-chamber views) or 2 sites (4-chamber view).
E06 ¼−0:163  yearsþ 19:56
E04 ¼−0:158  yearsþ 19:57
E0seplat ¼−0:150  yearsþ 18:95:
4. Discussion
Early diastolic LV function quantiﬁed by tissue Doppler as myocardi-
al velocity E′ demonstrates a 1% loss every year by physiological aging
from the 20th year of age onwards. This dominant relation was used
for discriminating normal function from dysfunction yielding quantita-
tive assignment to dysfunction. This approach allowed the study of de-
terminants of diastolic dysfunction independent of normal aging. The
resulting determinants were vascular function, diastolic blood pressure,
the driving force of myocardial perfusion, and the triglyceride/HDL
ratio, a marker of insulin resistance. In reversed sequence, these deter-
minants were also observed in the diabetes group, in addition to heart
rate, a measure of cardiac autonomic neuropathy.
4.1. Non-diabetic population and gender
The non-diabetic subjects had been selected as representative of a
population without overt cardiac disease but with the common cardio-
vascular risk proﬁle including overweight, in linewith the prevalence of
diastolic dysfunction in epidemiological studies [4]. The representative
character of our non-diabetic population has also been conﬁrmed by
comparison of echocardiographic referral individuals with a population
based selection [17], and further by the almost identical relation be-
tween E′ and age in two recent studies [7,18].
Diastolic parameters frommitral inﬂowDoppler have beenunaffect-
ed by sex similar to E′.
4.2. Age
The signiﬁcant inﬂuence of the unchangeable variable age on dia-
stolic function is well known [4,7,19].
As expressed by the coefﬁcients beta, this inﬂuence determines
N79% of diastolic function E′ but only 39% of systolic function S′ and,
therefore, requiresmathematical unmasking for E′. Accordingly, quanti-
ﬁcation of E′norm, was derived in the healthy subgroup and applied in
the whole non-diabetic group as respective estimated regression
equation (Fig. 1) demonstrating a decrease of E′ from a normal value
of 16 cm/s at 20 years to 7 cm/s at 80 years (1% reduction every year).
If the measured E′ equals the age related E′norm, the patient has normal
Table 4
Multivariable linear regression analysis.
Non-diabetic controls E′ − E′norm (cm/s)
Beta (95% CI) *p R2 †p
Model 1 0.086 0.004
PWV −0.445 (− .745 to− .145) 0.004
Model 2 (model 1 + LAVI) 0.134 0.001
PWV −0.446 (− .740 to− .152) 0.003
LAVI −0.017 (− .032 to− .002) 0.027
Model 3 (model 1 + diastolic BP) 0.155 0.001
PWV −0.400 (− .694 to− .107) 0.007
Diastolic BP −0.039 (− .067 to− .011) 0.008
Model 4: (model 3 after correction for each of the following variables)
a) Gender −0.398 (− .694 to− .103) 0.009 0.156 0.002
b) BMI −0.360 (− .658 to− .061) 0.019 0.186 b0.001
c) Systolic blood pressure −0.405 (− .697 to− .113) 0.007 0.175 0.001
d) Heart rate −0.403 (− .696 to− .110) 0.008 0.167 0.001
e) E/E′ −0.339 (− .636 to− .041) 0.026 0.124 0.012
f) IMT −0.446 (− .754 to− .138) 0.005 0.164 0.001
g) hsCRP −0.424 (− .764 to− .083) 0.015 0.172 0.002
Model 5 (model 3 + triglyceride/HDL ratio) 0.187 0.001
PWV −0.336 (− .659 to− .013) 0.042
Diastolic BP −0.037 (− .066 to− .009) 0.010
Triglyceride/HDL ratio −0.203 (− .380 to− .046) 0.018
T2D E′ − E′norm (cm/s)
Beta (95% CI) *p R2 †p
Model 1 0.081 b0.001
Triglyceride/HDL ratio −0.243 (− .366 to .057) b0.001
Model 2 (model 1 + diastolic BP) 0.137 b0.001
Triglyceride/HDL ratio −0.206 (− .366 to− .120) 0.001
Diastolic BP −0.032 (− .051 to− .013) 0.001
Model 3 (model 2 + PWV) 0.130 b0.001
Triglyceride/HDL ratio −0.190 (− .311 to− .068) 0.002
Diastolic BP −0.030 (− .049 to− .011) 0.002
PWV −0.022 (0.042 to− .002) 0.033
Model 4: (model 3 after correction for each of the following variables)
a) Gender −0.033 (− .055 to− .010) 0.006 0.141 b0.001
b) BMI −0.031 (− .053 to .008) 0.008 0.157 b0.001
c) Systolic blood pressure −0.028 (− .051 to− .006) 0.012 0.182 b0.001
d) E/E′ −0.033 (− .055 to− .011) 0.004 0.166 b0.001
e) IMT −0.034 (− .057 to− .012) 0.003 0.151 b0.001
f) Glucose −0.031 (− .057 to− .004) 0.022 0.152 b0.001
g) Creatinine −0.030 (− .053 to− .008) 0.009 0.175 b0.001
h) hsCRP −0.031 (− .055 to− .008) 0.010 0.143 0.001
Model 5 (model 3 + heart rate) 0.199 b0.001
Triglyceride/HDL ratio −0.195 (− .316 to− .074) 0.002
Diastolic BP −0.030 (− .048 to− .012) 0.002
PWV 0.029 (− .049 to− .009) 0.005
Heart rate 0.137 (− .010 to .264) 0.035
CI = tolerance interval, R2 and †p = level of signiﬁcance for the respectivemodels for controls in top panel or diabetes in bottompanel for E′ − E′norm as dependent variable. Inmodels 4
(a–h), cardiovascular factors or metabolic components are separately entered as possible confounders for correction and shown not to modify the contribution of pulse wave velocity in
panel a or triglyceride/HDL ratio in panel b. *p = level of signiﬁcance for the association between E′ − E′norm and the separate independent components of themodels or for PWVor heart
rate, respectively, after the adjustments indicated (models 4 a–h, respectively).
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ance limit may be found in actively training athletes or in untreated hy-
perthyroidism. Values b the lower 95% tolerance limit, indicate diastolic
dysfunction.
4.3. Comparison with traditional grading criteria of diastolic dysfunction
In the controls, grading of diastolic dysfunction demonstrated good
agreement between the dynamic criteria E′− E′norm and LV ﬁlling pres-
sure (Table 2) but in the diabetes patients only in the class of normal
function. 63% of diabetes patients were assigned to mild-moderately
raised E/E′ because a signiﬁcantly reduced mitral E velocity in grade 2
dysfunction effectively counteracted a relevant increase of E/E′ by the
decreased E′ (data not shown). As suggested also by our data in over-
weight and metabolic disease, elongation of the left atrium may be an
earlymechanismassociatedwith volume overload from impaired LV re-
laxation that counteracts a clinically relevant increase of ﬁlling pressureand merits further investigation [19–21]. Accordingly, high LV ﬁlling
pressures are not a pathognomonic feature of diastolic dysfunction in
metabolic disease, as opposed to hypertensive heart disease and prima-
ry cardiomyopathy.
Within the structural criteria for assessing diastolic dysfunction,
LAVI suggested more and LVMI less severity in both controls and diabe-
tes. These obvious discrepancies, however, are not entirely surprising
due to the heterogeneous etiology of diastolic dysfunction [20–23].
Our present data suggest that the traditional functional and structural
grading criteria for diastolic dysfunction are less useful in metabolic
heart disease.
4.4. Direct measurement of dynamic LV diastolic function
Structural alterations cannot be expected, if dysfunction is caused by
acute ischemia/hypoxia i.e. sudden onset of energy deﬁciency [2]. Dy-
namic changes in energy delivery are the major problem in metabolic
373H. von Bibra et al. / International Journal of Cardiology 182 (2015) 368–374disease [3,20]. Accordingly, this etiology of diastolic dysfunction re-
quires dynamic indicators. However, LV ﬁlling pressure, at least as
expressed by E/E′, has raised concern about the diagnosis of a mildly in-
creased degree of myocardial dysfunction [5,19] also in metabolic dis-
ease [20].
Surprisingly, no functional criterion has yet been identiﬁed as a reli-
able direct measure of active myocardial relaxation, although tissue
Doppler measurements have introduced E′ as a sensitive measure of di-
astolic myocardial function with prognostic potential [24,25]. Further-
more, the relationship between changes of E′ with those of exercise
capacity has recently been reported [4,26]. Finally, the feasibility and ro-
bustness of obtaining tissue Doppler variables even in patients difﬁcult
to image supports the use of E′ to characterize diastolic function [4,6,9].
In sequential studies, E′ proved sensitive to acute alterations of oxy-
gen supply in stress tests [11,25] or to postprandial dysmetabolism [27].
Its potential for monitoring therapeutic effectiveness has been demon-
strated for improvement of metabolic control, high blood pressure, hy-
perlipidemia or for amelioration of insulin resistance either by diet [26],
exercise [28] or pharmacological therapy [8]. In crossectional studies,
however, the strong age dependence of E′ implied a broad range of
values thereby limiting the evaluation of diastolic dysfunction. Howev-
er, the quantitative approach with E′− E′norm would allow insight into
the impact of noxious inﬂuences.
4.5. The dynamic metabolic nature of diastolic dysfunction
In elderly individuals, limited exercise tolerance often results from
age-dependent deterioration of diastolic function. Of concern is a grow-
ing population of middle-aged subjects with impaired exercise toler-
ance and diastolic dysfunction due to increasing prevalence of
overweight, diabetes, hypertension and atherosclerotic disease.
Diastolic dysfunction consists of 1) slow LV relaxation and LV ﬁlling
in early diastole and 2) increasedmyocardial stiffness predominantly in
late diastole, the mechanism for which is poorly understood.
Firstly, slow relaxation in early diastole results from abnormal cross-
bridge detachment, calcium uptake by the sarcoplasmic reticulumor al-
tered nitric oxide (NO) signaling [1,4]. Since cross-bridge detachment is
an energy consuming process, slow relaxationmay reﬂect a myocardial
energy deﬁcit [2,29] that may be due to microvascular dysregulation
induced by insulin resistance and/or a low intra-mitochondrial
creatine-phosphate/adenosine-triphosphate ratio [3,8]. Integration
of these multiple covariates results in a myocardial energy supply/
demandmismatchwith reduced cardiac efﬁcacy in insulin resistance
or diabetes [8,30]. This untenable situation of reduced energy avail-
ability but increased myocardial oxygen requirement is exacerbated
by disturbed ventricular–arterial coupling, increases in heart rate or
in sympathetic tone [1,7,30].
Secondly, increased myocardial stiffness in late diastole suggests
structural myocardial alterations, that may relate to the extracellular
matrix in terms of collagen characteristics [24], interstitial ﬁbrosis
and inﬂammation [31], steatosis in insulin resistance and/or advanced
glycemic end-products (AGE) in diabetes whereas the intracellular
components relate to pressure induced or insulin/growth hormone in-
duced myocellular hypertrophy and to the cytoskeletal protein titin [4,
23].
4.6. Metabolic determinants of dysfunction in metabolic disease
The new approach E′− E′norm allows characterization of the deter-
minants of diastolic dysfunction independent from dominant but un-
changeable age and its associated risks. Our data are the ﬁrst to
demonstrate that these determinants in non-diabetic individuals are
vascular stiffness, diastolic blood pressure and insulin resistance. This
corroborates the impact of arterio-ventricular coupling [1] on cardiac
function and clariﬁes the pivotal role of myocardial perfusion being
driven by diastolic blood pressure. Of interest, the onset, severity andduration of insulin resistance inﬂuenced proinﬂammatory endothelial
activation in a primate model of diet induced obesity [32] in line with
our data that insulin resistance or serum insulin levels demonstrate ut-
most impact on the degree of dysfunction most likely via endothelial
dysfunction. There is increasing awareness regarding the associations
of insulin resistance with diastolic dysfunction, cardiomyopathy and
heart failure [20,30]. Concordant with our data, hyperglycemia is not
the only driver of these mechanisms [20,27]. Interestingly, no variable
of cardiac structure plays a signiﬁcant role in diabetic diastolic dysfunc-
tion but rather insulin resistance, diastolic blood pressure, vascular
function, and autonomic neuropathy. The greatest contributor to dia-
stolic dysfunction is the underlying insulin resistance. As a therapeutic
consequence, life stylemodiﬁcations [26,28] and pharmaceutical strate-
gies that improve insulin sensitivity should be vigorously applied [8,12,
26] according to a paradigm shift of understanding HFpEf as an entity of
comorbid lesions that are often based on metabolic dysfunction, rather
than focusing on myocardial/vascular structure alone. In patients with
diastolic dysfunction and metabolic disease, accordingly, metabolic
therapy should be assessed in future studies and patients with relevant-
ly elevated ﬁlling pressures should be reevaluated after treatment of
volume overload.
4.7. Limitations
Tissue Doppler based E′was sampled in 6 annular siteswhereas clin-
ical routine prefersmeasurements from the septal and lateral wall, lead-
ing to a slightly different regression equation and cut off level. For any
selection ofmeasurement sites and also for the use of color tissue Dopp-
ler with its intrinsically lower velocities, the respective regression equa-
tions may be implemented in the ultrasound systems to facilitate
correct application.
5. Conclusion
Because the dominant impact of aging on early diastolic function E′
requires mathematical unmasking, the estimated regression equation
for E′norm over age was obtained in healthy individuals to quantify indi-
vidual dysfunction by comparing the actual E′ to the calculated E′norm.
This reference data is of clinical importance especially to differentiate
patients with (preclinical) diastolic dysfunction. Additionally, it im-
proves the selection of adequate study populations for clinical trials
aimed at treatment or prevention of HFpEF. Furthermore it allows for
more speciﬁc research into the determinants of diastolic dysfunction
with its broad range of etiologic factors includingmyocardial energy de-
ﬁciency in overweight and diabetes. Acknowledging the epidemic in-
crease of metabolic disease, future therapeutic interest should focus
on postprandial metabolic effects and their implications for insulin sig-
naling, NO availability, oxidative stress generation and endothelial and
vascular function. This approach offers earlier implementation of thera-
py for preventive action and the potential for more causal therapeutic
strategies for patients with HFpEF who face a dismal prognosis without
effective therapy.
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